Indomethacin sodium

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Indomethacin is an inhibitor of the enzyme cyclooxygenase 1 and 2. Indomethacin elicits side effects in gastrointestinal tract, kidney and cerebrum.

Indomethacin is an inhibitor of the enzyme cyclooxygenase 1 and 2. Indomethacin elicits side effects in gastrointestinal tract, kidney and cerebrum.

Indomethacin is an inhibitor of the enzyme cyclooxygenase 1 and 2. Indomethacin elicits side effects in gastrointestinal tract, kidney and cerebrum.

Indomethacin is an inhibitor of the enzyme cyclooxygenase 1 and 2. Indomethacin elicits side effects in gastrointestinal tract, kidney and cerebrum.

Biochem/physiol Actions Cyclooxygenase (COX) inhibitor that is relatively selective for COX-1. Used as a non-selective inhibitor of cyclooxygenases, COX1 and COX2, leading to reduced prostaglandin biosynthesis from arachidonic acid.

Biochem/physiol Actions Cyclooxygenase (COX) inhibitor that is relatively selective for COX-1. Used as a non-selective inhibitor of cyclooxygenases, COX1 and COX2, leading to reduced prostaglandin biosynthesis from arachidonic acid.

Biochem/physiol Actions Cyclooxygenase (COX) inhibitor that is relatively selective for COX-1. Used as a non-selective inhibitor of cyclooxygenases, COX1 and COX2, leading to reduced prostaglandin biosynthesis from arachidonic acid.

Indomethacin, an anti-inflammatory agent, inhibits Cox-1 and Cox-2 (cyclooxygenases) with selectivity for Cox-1 (IC50 of 230 nM) over Cox-2 (IC50 of 630 nM). Additionally, Indomethacin displays adipogenic actions via binding and activation of

Indomethacin, an anti-inflammatory agent, inhibits Cox-1 and Cox-2 (cyclooxygenases) with selectivity for Cox-1 (IC50 of 230 nM) over Cox-2 (IC50 of 630 nM). Additionally, Indomethacin displays adipogenic actions via binding and activation of

Indomethacin, an anti-inflammatory agent, inhibits Cox-1 and Cox-2 (cyclooxygenases) with selectivity for Cox-1 (IC50 of 230 nM) over Cox-2 (IC50 of 630 nM). Additionally, Indomethacin displays adipogenic actions via binding and activation of